

Nashville Hematology Conference 2025 Financial Disclosures

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly mitigated according to PIM policy. PIM is committed to providing its learners with high-quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity. These relationships have been mitigated:

Jonathan Abbas, MD reports serving on a speakers bureau/honoraria for non-CME for BMS, Abbvie, Incyte, Takeda, and GSK. He also serves as a consultant/advisory board member for Aravive, Alpine Bioscience, Aveo, Nimbus, Arcus, BMS, Exelixis, Merck, Sanofi, Seagen, Eisai, and Xencor.

Inhye Ahn, MD reports receiving grant/research support from BeiGene and Lilly. She also serves as a consultant/advisory board member for AstraZeneca, BeiGene, and Lilly.

Susan Bal, MD reports receiving grant/research support from BMS, AbbVie, BeiGene, and Fate Therapeutics. She also serves as a consultant/advisory board member for BMS, Janssen, AbbVie, AstraZeneca, and Pfizer.

Rahul Banerjee, MD, FACP reports receiving grant/research support from Abbvie, BMS, JNJ, Novartis, Pack Health, Prothena, and Sanofi. He also serves as a consultant/advisory board member for Adaptive Biotech, BMS, Caribou Biosciences, Genentech/Roche, GSK, Karyopharm, Legend Biotech, JNJ, Pfizer, Sanofi Pasteur, and SparkCures.

Jacqueline Barrientos, MD reports receiving grant/research support from Janssen, Beigene, and Abbvie. She also serves as a consultant/advisory board member for Janssen and Beigene.

Jesus Berdeja reports receiving grant/research support from 2 Seventy Bio, Abbvie, Amgen, BMS, C4 Therapeutics, Caribou Biosciences, CARsgen, Cartesian Therapeutics, Celularity, CRISPR Therapeutics, Fate Therapeutics, Genentech, GSK, Ichnos Sciences, Incyte, Janssen, Juno Therapeutics, K36 Therapeutics. Karyopharm, Lilly, Novartis, Poseida, Roche, Sanofi, and Takeda. He also serves as a consultant/advisory board member for AstraZeneca, BMS, Caribou Biosciences, Galapagos, Janssen, K36 Therapeutics, Kite Pharma, Legend Biotech, Pfizer, Regeneron, Roche, Sanofi, Sebia, and Takeda.

Michael Byrne, MD reports being an employee/owner at Tennessee Oncology.

Natalie Callander, MD had no relevant financial relationships to report.

Hetty Carraway, MD, MBA reports receiving grant/research support from BMS/Celgene. She also serves as a consultant/advisory board member for Abbvie, BMS, Agios, Daiichi, Takeda, Jazz, Novartis, Kura, Stemline, and Servier.

Carla Casulo, MD reports being an employee/owner at the University of Rochester. She reports receiving grant/research support from Genmab, Gilead, and Genentech. She reports serving on a speakers bureau/honoraria for non-CME for BMS, Abbvie, and Genentech. She also serves as a consultant/advisory board member for BMS, Abbvie, and Genentech. Other financial or material support: ASH & LRF leadership.

Jason Chandler, MD reports being an employee/owner at West Cancer Center. He reports receiving grant/research support from BMS - 2 open clinical trial, Abvie - 1 open clinical trial, Roche - 1 open clinic trial, and Morphosys (Incyte) - 1 closed clinical trial. He reports serving on a speakers bureau/honoraria for non-CME for Amgen and BeiGene. He also serves as a consultant/advisory board member for Janssen, Seagen, and Kite.

Ajai Chari, MD reports receiving grant/research support from Janssen. He reports serving on a speakers bureau/honoraria for non-CME for curio-science, Ideology, MJH, and Octopharm. He also serves as a consultant/advisory board member for Abbvie, Adaptive, Amgen, Antengene, Bristol Myers Squibb, Forus, Genentech/Roche, Glaxo Smith Klein, Janssen, Karyopharm, Millenium/Takeda, and Sanofi/Genzyme.

Hearn Cho, MD, PhD reports receiving grant/research support from Genentech/Roche, BMS, and Takeda. Other financial or material support: Employment: The Multiple Myeloma Research Foundation.

Elise Chong, MD reports receiving grant/research support from AbbVie, AstraZeneca, CARGO, Genentech, Genmab, Nurix. She reports having served as a consultant/advisory board member for AstraZeneca, AbbVie/Genmab, Beigene, DAVA Oncology. Reports patent Holder/Royalties from Patent related to FGFR2 managed by the University of Pennsylvania.

Adam Cohen, MD reports receiving grant/research support from GSK, Janssen, Genentech, and BMS. He also serves as a consultant/advisory board member for Daiichi, Pharmacyclics, and Abbvie.

Callie Coombs, MD reports receiving grant/research support from Carnabio, Beigene, Lilly, and AbbVie. She reports serving on a speakers bureau/honoraria for non-CME for AstraZeneca, Beigene, Lilly, Genentech, and Abbvie. She also serves as a consultant/advisory board member for AstraZeneca, Beigene, Lilly, Genentech, Abbvie, Janssen, Allogene, and Mingsight. She reports non-mutual funds, such as stock ownership/stock options from Pfizer, Geron, and Bluebird Bio.

Caitlin Costello, MD serves as a consultant/advisory board member for Astra Zeneca, Janssen, BMS, Pfizer, Karyopharm, Genentech, and Regeneron.

Faith Davies, MD, MBBCh serves as a consultant/advisory board member for BMS, Janssen, Meridian, and Takeda.

Natalie Dickson, MD, MMHC, FACP reports being an employee/owner at Tennessee Oncology.

Christopher Flowers, MD, MS reports being an employee/owner at Employee- MD Anderson. Reports receiving grant/research support from 4D, Abbvie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Collectis EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen Pharmaceutical, Kite, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm, Burroughs Wellcome Fund, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation, Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research. Serves as a consultant/advisory board member for Abbvie, Bayer, BeiGene, Celgene, Denovo Biopharma, Foresight Diagnostics, Genentech/Roche, Genmab, Gilead, N-Power Medicine, and Pharmacyclics/Janssen. He also reports non-Mutual funds Stock Ownership/Stock options for Foresight Diagnostics, N-Power Medicine.

Mindy Hsiao, MD had no relevant financial relationships to report.

Boyu Hu, MD reports receiving grant/research support from Genentech, Celgene, CRISPR Therapeutics, Morphosys AG, Caribou Biosciences, Repare Therapeutics, Artiva Biotherapeutics, Newave, AstraZeneca, and ImmPACT Bio. He serves as a consultant/advisory board member for Regeneron, Caribou Biosciences, Abbvie, Kite, Pfizer, Bristol-Meyer Squibb, ADC Therapeutics, Genentech, ImmPACT Bio, and SeaGen.

Ryan Jacobs, MD reports receiving grant/research support from Pharmacyclics, AstraZeneca, Lilly, Abbvie, Beigene, and Regeneron. He reports serving on a speakers bureau/honoraria for non-CME for Abbvie, Adaptive, Beigene, and AstraZeneca. He serves as a consultant/advisory board member for Abbvie, AstraZeneca, SecuraBio, Genentech, Beigene, Janssen, Lilly, and Galapagos.

Amrita Krishnan, MD, FACP serves as a consultant/advisory board member for GSK, Janssen, Adaptive, Arcelx, Roche, Sanofi, and Abbvie. He also reports non-Mutual funds Stock Ownership/Stock options for BMS. Other financial or material support: Advisory Board: Johnson and Johnson.

Andrew Kuykendall, MD reports receiving grant/research support from MorphoSys, BMS, GSK, Protagonist, Janssen, Geron, Novartis, and Blueprint Medicines. He serves as a consultant/advisory board member for Celgene/BMS, Incyte, AbbVie, Imago, PharmaEssentia, CTI Biopharma, MorphoSys, GSK, Karyopharm, Silence Therapeutics, Geron, and Blueprint Medicines.

Matthew Lunning, DO, FACP reports receiving grant/research support from AbbVie, BMS, FATE Therapeutics, and Kite/Gilead. He serves as a consultant/advisory board member for AbbVie, Acrotech, ADC Therapeutics, AZ, BMS, FATE Therapeutics, Genentech, Ipsen, Janssen, Kite/Gilead, Loxo/Lilly, Recordati, Regeneron, Pfizer, and Veeva.

Sham Mailankody, MBBS reports being an employee/owner at Memorial Sloan Kettering Cancer Center. Reports receiving grant/research support from Leukemia Lymphoma Society, BMS, Janssen, Allogene, Caribou Therapeutics, Fate Therapeutics, Takeda Oncology, and National Cancer Institute. He reports serving on a speakers bureau/honoraria for non-CME for Physician Education Resource, Plexus education, and MJH Life Sciences. He serves as a consultant/advisory board member for Legend Biotech, Evicore, Janssen, Optum, AbbVie, ArcellX, Bristol Myers Squibb, and Galapagos Therapeutics.

John Mascarenhas, MD reports being an employee/owner at Mount Sinai. He reports receiving grant/research support from Incyte, Novartis, Abbvie, CTI/SOBI, BMS, PharemaEssentia, Geron, Kartos, Karyopharm, Disc, and Ajax. He serves as a consultant/advisory board member for Incyte, MorphoSys, Novartis, Abbvie, BMS, Roche, PharmaEssentia, Disc, Keros, Blueprint Medicines, Merck, CTI/SOBI, Kartos, Karyopharm, Geron, and GSK.

Oreofe Odejide, MD, MPH serves as a consultant/advisory board member for AstraZeneca.

Neil Palmisiano, MD, MS serves as a consultant/advisory board member for Amgen, BMS, Servier, and Rigel.

Krina Patel, MD, MSc reports being an employee/owner UT MD Anderson Cancer Center. Serves as a consultant/advisory board member for BMS/Celgene, Johnson and Johnson/Janssen, Legend Biotech, Takeda, Pfizer, Regeneron, Novartis, Kite, Oricel, Abbvie, Genentech, Sanofi, and Biora.

Tycel Phillips, MD reports receiving grant/research support from Abbvie, Genentech, Sobi, Bayer, and BMS. He serves as a consultant/advisory board member for Abbvie, ADCT, AstraZeneca, Bayer, Beigene, BMS, Caribou, Eli Lilly, Genentech, Genmab, Gilead, Incyte, Pfizer, Pharmacyclics, Merck, Regeneron, Seattle Genetics, and Xencor. Other financial or material support LLS (grant), Cures within Reach (grant).

Noopur Raje, MD reports receiving grant/research support from Pfizer. He serves as a consultant/advisory board member for BMS, J and J, Pfizer, AstraZeneca, GSK, Regeneron, Genetch, Caribou, and Immuneel.

Joanna Rhodes, MD reports receiving grant/research support from AbbVie, Acerta, Janssen, Loxo Oncology, Oncternal Therapeutics, Pharmacyclics, and VelosBio. She reports serving on a speakers bureau/honoraria for non-CME for AbbVie, ADC Therapeutics, Beigene, Epizyme, Genentech, Janssen, MorphoSys, Pharmacyclics, Seagen, TG Therapeutics, and Verastem.

She serves as a consultant/advisory board member for AbbVie, ADC Therapeutics, Beigene, Epizyme, Genentech, Janssen, MorphoSys, Pharmacyclics, Seagen, TG Therapeutics, and Verastem.

Joshua Richter, MD, FACP reports serving on a speakers bureau/honoraria for non-CME for Janssen, BMS, Sanofi, and Adaptive Biotechnologies. He serves as a consultant/advisory board member for Janssen, BMS, Pfizer, Karyopharm, Sanofi, Takeda, Genentech, Abbvie, Regeneron, Forus, and Menarini.

Sarah Rutherford, MD reports receiving grant/research support from Constellation, Genentech/Roche, and Karyopharm. She serves as a consultant/advisory board member for ADC, BMS, Genmab, Karyopharm, and Pfizer/Seagen.

Stephen Schleicher, MD, MBA reports being an employee/owner Main Street Health, Tennessee Oncology. Reports serving on a speakers bureau/honoraria for non-CME for Beigene. He reports non-mutual funds, such as stock ownership/stock options from Main Street Health, OneOncology, and ThymeCare.

Mazyar Shadman, MD, MPH reports receiving grant/research support from Mustang Bio, Genentech, AbbVie, Beigene, AstraZeneca, Genmab, Morphosys/Incyte and Vincerx, and Pharmacyclics. Reports serving on a speakers bureau/honoraria for non-CME for ADC Therapeutics. He reports serving as a consultant/advisory board member for Abbvie, Genentech, AstraZeneca, Genmab, Janssen, Beigene, Bristol Myers Squibb, Morphosys/Incyte, Kite Pharma, Eli Lilly, Fate therapeutics, Nurix and Merck, MEI Pharma, and Pharmacyclics. He reports non-mutual funds, such as stock ownership/stock options from Koi Biotherapeutic.

Alan Skarbnik, MD reports serving on a speakers bureau/honoraria for non-CME for AstraZeneca, Abbvie, ADC Therapeutics, Beigene, BMS, GenMab, Genentech, Jazz Therapeutics, Kite Pharma, Lilly, and SeaGen. He serves as a consultant/advisory board member for Alexion, Abbvie, AstraZeneca, Celgene, BMS, Epizyme, Lilly, Kite Pharma, and SeaGen.

Ronald Tang, DO had no relevant financial relationships to report.

Peter Voorhees, MD reports receiving grant/research support from Abbvie, GSK, Johnson and Johnson, and Regeneron (all to institutions). He serves as a consultant/advisory board member for Abbvie, Ascentage Pharma, Astra Zeneca, BMS, GSK, Johnson and Johnson, Karyopharm, Pfizer, Regeneron, and Sanofi.

Tarun Wasil, MD reports being an employee/owner NYCBS. Reports serving on a speakers bureau/honoraria for non-CME for AZN, Eli Lilly and GSK. He serves as a consultant/advisory board member for Beigene and Pfizer. He reports non-mutual funds, such as stock

ownership/stock options from a portfolio with UBS that includes Biotechs. Reports patent Holder/Royalties from CD38 as a blood test.

Jason Westin, MD reports receiving grant/research support from ADC therapeutics, allogene, AstraZeneca, BMS, Genentech, Janssen, Kite/Gilead, Morphosys/Incyte, Novartis, Nurix, and Regeneron. He serves as a consultant/advisory board member for Abbvie, Allogene, ADC Therapeutics, AstraZeneca, BMS, Genentech, GenMab, Janssen, Kite/Gilead, Morphosys/Incyte, Novartis, Nurix, Regeneron, and SeaGen.

Amer Zeidan, MBBS reports receiving grant/research support from AbbVie, Amgen, Astex, Bristol-Meyers Squibb, Celgene, Geron, Kura, Novartis, Otsuka, Shattuck Labs, and Syros. He serves as a consultant/advisory board member for AbbVie, Agios, Akeso Pharma, ALX Oncology, Amgen, Astellas, BeiGene, BioCryst, Bristol-Meyers Squibb, Boehringer-Ingelheim, Celgene, Chiesi, Daiichi Sankyo, Epizyme, Faron, Genentech, Geron, Gilead, Glycomimetics, Hikma, Janssen, Karyopharm, Keros, Kura, Kyowa Kirin, Lava Therapeutics, Mendus, Notable, Novartis, Orum, Otsuka, Pfizer, Regeneron, Rigel, Schrodinger, Servier, Sumitomo, Syndax, Syros, Taiho, Takeda, Treadwell, Vincerx, and Zentalis.